Key points from article :
Doron Therapeutics, a biotechnology company focused on regenerative treatments for musculoskeletal conditions, has raised $11 million in a Series A funding round to advance its lead drug, MOTYS, into Phase 3 clinical trials. MOTYS is an innovative intra-articular biologic therapy derived from placental tissue, targeting symptomatic knee osteoarthritis (OA). It combines anti-inflammatory, anti-catabolic, and pro-anabolic effects, aiming to reduce pain, protect cartilage, and stimulate tissue regeneration. Remarkably, a single injection has shown effects lasting up to 12 months.
Originally developed by Bioventus, MOTYS has demonstrated promising results in preclinical and Phase 2 trials, with over 200 participants reporting significant improvements in knee pain and function over 26 weeks. These findings were presented at the Osteoarthritis Research Society International (OARSI) World Congress, underscoring the drug's potential as a long-lasting alternative to corticosteroids and hyaluronic acid.
The funding round was led by SPRIM Global Investments, with new board members, including Karen Zaderej, joining to bolster Doron’s strategic direction. CEO Alessandra Pavesio emphasized the urgent need for effective non-surgical treatments for OA, expressing optimism that MOTYS could help patients regain mobility and improve their quality of life. This funding milestone marks a significant step toward transforming OA care and addressing a growing global health challenge.
